However, the question of whether PD‐1/PD‐L1 inhibitors hold efficacy for PD‐L1 low expression (CPS < 1 or TPS < 1%) patients has remained unanswered, a query that has garnered heightened attention in other malignancies such as melanoma, renal cell carcinoma, non‐small cell lung cancer (NSCLC), and esophageal carcinomas.19, 20. Here, CD274 is linked to renal cell carcinoma.